Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis 2013-2018 and Forecast 2019-2025

Publisher Name :
Date: 16-Oct-2018
No. of pages: 133
Inquire Before Buying

This report studies the Chemotherapy Induced Peripheral Neuropathy Treatment market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the Chemotherapy Induced Peripheral Neuropathy Treatment market by product type and applications/end industries.

In the last several years, global market of Chemotherapy Induced Peripheral Neuropathy Treatment developed rapidly, with an average growth rate of 6.78%. In 2017, global revenue of Chemotherapy Induced Peripheral Neuropathy Treatment is nearly 1302 M USD; the actual Sales is about 77876 thousand units.

The major players in global Chemotherapy Induced Peripheral Neuropathy Treatment market include

Aptinyx

Asahi Kasei Pharma

Regenacy Pharmaceuticals

MAKScientific

Metys Pharmaceuticals

Nemus Bioscience

PledPharma

Sova Pharmaceuticals

DermaXon

Immune Pharmaceuticals

Kineta

Krenitsky Pharmaceuticals

PeriphaGen

Apexian Pharma

WinSanTor

Solasia Pharma

Geographically, this report is segmented into several key Regions, with Sales, revenue, Market Share (%) and Growth Rate (%) of Chemotherapy Induced Peripheral Neuropathy Treatment in these regions, from 2013 to 2025 (forecast), covering

North America

Europe

Asia-Pacific

South America

Middle East and Africa

On the basis of product, the Chemotherapy Induced Peripheral Neuropathy Treatment market is primarily split into

Calcium Channel a2-delta Ligands

Antidepressants

Opioids

Others

On the basis of applications the Chemotherapy Induced Peripheral Neuropathy Treatment market is primarily split into

Platinum Agents

Taxanes

Vinca Alkaloids

Others

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis 2013-2018 and Forecast 2019-2025

Table of Contents
1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview 1
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview 1
1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Types (Product Category) 1
1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Comparison by Types (2013-2025) 1
1.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Types in 2017 2
1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Applications 2
1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Comparison by Applications (2013-2025) 2
1.3.2 Platinum Agents 3
1.3.3 Taxanes 4
1.3.4 Vinca Alkaloids 4
1.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market by Regions 5
1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Regions 5
1.4.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2013-2025) 6
1.4.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2013-2025) 7
1.4.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2013-2025) 8
1.4.5 South America Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2013-2025) 9
1.4.6 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2013-2025) 10
1.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size 11
1.5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Status and Outlook (2013-2025) 11
1.5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Status and Outlook (2013-2025) 12
1.6 Global Chemotherapy Induced Peripheral Neuropathy Treatment Number of Patients by Regions 2017 12
2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competition by Manufacturers/Brand 13
2.1 Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Products and Clinical Stages 13
2.2 Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Headquarters, Established Date and Product Types 14
2.3 Major Cancer Analysis 15
2.3.1 Colorectal Cancer 15
2.3.2 Lung Cancer 17
2.3.3 Pancreatic Cancer 19
2.3.4 Breast Cancer 21
2.3.5 Prostate Cancer 22
2.3.6 Other Cancer 24
3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue by Regions 26
3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Regions (2013-2018) 26
3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Regions (2013-2018) 28
3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2013-2018) 30
3.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2013-2018) 30
3.5 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2013-2018) 31
3.6 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2013-2018) 32
3.7 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2013-2018) 32
3.8 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2013-2018) 33
4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price Trend by Types 34
4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Types (2013-2018) 34
4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Types (2013-2018) 36
4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2013-2018) 38
4.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth by Type (2013-2018) 38
5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis by Applications 39
5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Applications (2013-2018) 39
5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Applications (2013-2018) 41
6 Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment Industry Key Manufacturers 42
6.1 Aptinyx Inc 42
6.1.1 Company Profile 42
6.1.2 Product Information 43
6.2 Asahi Kasei Pharma Corp 44
6.2.1 Company Profile 44
6.2.2 Product Information 45
6.3 Regenacy Pharmaceuticals 46
6.3.1 Company Profile 46
6.3.2 Product Information 46
6.4 MAKScientific LLC 47
6.4.1 Company Profile 47
6.4.2 Product Information 48
6.5 Metys Pharmaceuticals AG 49
6.5.1 Company Profile 49
6.5.2 Product Information 49
6.6 Nemus Bioscience Inc 50
6.6.1 Company Profile 50
6.6.2 Product Information 51
6.7 PledPharma 51
6.7.1 Company Profile 51
6.7.2 Product Information 52
6.8 Sova Pharmaceuticals Inc 53
6.8.1 Company Profile 53
6.8.2 Product Information 54
6.9 DermaXon LLC 54
6.9.1 Company Profile 54
6.9.2 Product Information 55
6.10 Immune Pharmaceuticals Inc 55
6.10.1 Company Profile 55
6.10.2 Product Information 56
6.11 Kineta Inc 57
6.11.1 Company Profile 57
6.11.2 Product Information 58
6.12 Krenitsky Pharmaceuticals Inc 58
6.12.1 Company Profile 58
6.12.2 Product Information 59
6.13 PeriphaGen 60
6.13.1 Company Profile 60
6.13.2 Product Information 60
6.14 Apexian Pharma 61
6.14.1 Company Profile 61
6.14.2 Product Information 62
6.15 WinSanTor 62
6.15.1 Company Profile 62
6.15.2 Product Information 63
6.16 Solasia Pharma K.K. 64
6.16.1 Company Profile 64
6.16.2 Product Information 65
7 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Cost Analysis 66
7.1 Chemotherapy Induced Peripheral Neuropathy Treatment Drugs R&D Cost Analysis 66
7.1.1 Clinical Phase Costs 67
7.1.2 Capitalized Costs 68
7.2 Proportion of Manufacturing Cost Structure 69
7.2.1 Raw Materials 69
7.2.2 Labor Cost 70
7.2.3 Manufacturing Expenses 77
7.3 Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment Drugs 78
8 Industrial Chain, Sourcing Strategy and Downstream Buyers 79
8.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis 79
8.2 Upstream Raw Materials Sourcing 80
8.3 Downstream Buyers 80
9 Marketing Strategy Analysis, Distributors/Traders 83
9.1 Marketing Channel 83
9.1.1 Direct Marketing 83
9.1.2 Indirect Marketing 83
9.1.3 Marketing Channel Development Trend 83
9.2 Market Positioning 84
9.2.1 Pricing Strategy 84
9.2.2 Brand Strategy 85
10 Market Effect Factors Analysis 87
10.1 Technology Progress/Risk 87
10.2 Consumer Needs/Customer Preference Change 88
10.3 Economic/Political Environmental Change 88
11 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast 97
11.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue Forecast 97
11.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate Forecast (2019-2025) 97
11.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate Forecast (2019-2025) 98
11.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue Forecast by Regions (2019-2025) 98
11.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue Forecast (2019-2025) 100
11.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue Forecast (2019-2025) 102
11.2.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue Forecast (2019-2025) 104
11.2.4 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue Forecast (2019-2025) 106
11.2.5 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue Forecast (2019-2025) 108
11.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price Forecast by Type (2019-2025) 109
11.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Application (2019-2025) 111
12 Research Findings and Conclusion 113
13 Methodology and Data Source 114
13.1 Methodology/Research Approach 114
13.1.1 Research Programs/Design 114
13.1.2 Market Size Estimation 115
13.1.3 Market Breakdown and Data Triangulation 116
13.2 Data Source 117
13.2.1 Secondary Sources 117
13.2.2 Primary Sources 118
13.3 Disclaimer 119
13.4 Author List 120
List of Tables and Figures
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) Comparison by Types (2013-2025) 1
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Types in 2017 2
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) Comparison by Applications (2013-2025) 2
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Applications in 2017 3
Table Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) Comparison by Regions 2013-2025 5
Figure North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) and Growth Rate (2013-2025) 6
Figure Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) and Growth Rate (2013-2025) 7
Figure Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) and Growth Rate (2013-2025) 8
Figure South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) and Growth Rate (2013-2025) 9
Figure Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) and Growth Rate (2013-2025) 10
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) Status and Outlook (2013-2025) 11
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) Status and Outlook (2013-2025) 12
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Number of Patients by Regions 2017 (Thousand) 12
Table Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Products and Clinical Stages 13
Table Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Headquarters and Established Date 14
Table Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Category 14
Top 20 Countries Highest Incidence of Colorectal Cancer in 2016 16
Top 20 Countries Highest Incidence of Lung Cancer in 2016 17
Figure Percent of New Cases by Age Group: Lung Cancer 18
Figure Percent of Deaths by Age Group: Lung Cancer 19
Top 20 Countries Highest Incidence of Pancreatic Cancer in 2016 20
Top 20 Countries Highest Incidence of Breast Cancer in 2016 22
Figure Percent of New Cases by Age Group: Prostate Cancer 23
Figure Percent of Deaths by Age Group: Prostate Cancer 24
Figure Estimated Prostate Cancer Incidence Worldwide in 2016 24
Information about World Cancer Statistics for the Most Common Cancers (excluding non-melanoma Skin Cancer) in 2016 25
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) by Regions (2013-2018) 26
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Regions (2013-2018) 26
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Regions (2013-2018) 27
Figure 2017 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Regions 27
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) by Regions (2013-2018) 28
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Regions (2013-2018) 28
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Regions (2013-2018) 29
Figure 2017 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Regions 29
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit), Revenue (M USD), Price (USD/Unit) and Gross Margin (2013-2018) 30
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit), Revenue (M USD), Price (USD/Unit) and Gross Margin (2013-2018) 30
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume (K Unit) by Regions (2013-2018) 30
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Value (M USD) by Regions (2013-2018) 31
Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit), Revenue (M USD), Price (USD/Unit) and Gross Margin (2013-2018) 31
Table Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit), Revenue (M USD), Price (USD/Unit) and Gross Margin (2013-2018) 32
Table South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit), Revenue (M USD), Price (USD/Unit) and Gross Margin (2013-2018) 32
Table Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit), Revenue (M USD), Price (USD/Unit) and Gross Margin (2013-2018) 33
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) by Types (2013-2018) 34
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Types (2013-2018) 34
Figure Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Types (2013-2018) 35
Figure 2017 Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Types 35
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) by Types (2013-2018) 36
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Types (2013-2018) 36
Figure Revenue Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Types (2013-2018) 37
Figure 2017 Revenue Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Types 37
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (USD/Unit) by Types (2013-2018) 38
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth by Type (2013-2018) 38
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) by Applications (2013-2018) 39
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Applications (2013-2018) 39
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Applications (2013-2018) 40
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Applications in 2017 40
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Applications (2013-2018) 41
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Applications (2013-2018) 41
Table Aptinyx Inc Company Profile 42
Table Asahi Kasei Pharma Corp Company Profile 44
Figure Chemotherapy Induced Peripheral Neuropathy Treatment Product Picture of Asahi Kasei Pharma Corp 45
Table Regenacy Pharmaceuticals Company Profile 46
Table MAKScientific LLC Company Profile 47
Figure Chemotherapy Induced Peripheral Neuropathy Treatment Product Picture of MAKScientific LLC 48
Table Metys Pharmaceuticals AG Company Profile 49
Table Nemus Bioscience Inc Company Profile 50
Figure Chemotherapy Induced Peripheral Neuropathy Treatment Product Picture of Nemus Bioscience Inc 51
Table PledPharma Company Profile 51
Figure Chemotherapy Induced Peripheral Neuropathy Treatment Product Picture of PledPharma 52
Table Sova Pharmaceuticals Inc Company Profile 53
Table DermaXon LLC Company Profile 54
Table Immune Pharmaceuticals Inc Company Profile 55
Table Kineta Inc Company Profile 57
Table Krenitsky Pharmaceuticals Inc Company Profile 58
Table PeriphaGen Company Profile 60
Table Apexian Pharma Company Profile 61
Table WinSanTor Company Profile 62
Table Solasia Pharma K.K. Company Profile 64
Figure Chemotherapy Induced Peripheral Neuropathy Treatment Product Picture of Solasia Pharma K.K. 65
Figure Typical Phases from Research to the Market for a Drug Candidate 67
Table Out-of-pocket Preclinical and Clinical Period Cost per Investigational Biopharmaceutical Compound 68
Table Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound 69
Figure Manufacturing Cost Structure of Chemotherapy Induced Peripheral Neuropathy Treatment Drugs 69
Figure Assessment of API Manufacturing Cost By Region 70
Figure USA Overview of Average Hourly Wages 2015-2016 (USD/Hour) 71
Figure USA Overview of Labor Costs 2013-2016 (110 Index Points) 71
Figure Cost of Employing a Factory Worker 73
Figure 2015 Estimated Labor Costs for the Whole Economy in Europe 74
Figure Monthly Minimum Wages in Asia 2016 75
Figure China Overview of Average Yearly Wages 2015-2016 (CNY/Year) 76
Figure Japan Overview of Average Monthly Wages 2015-2016(JPY Thousand/Month) 76
Table 2015 Global Electricity Price of Industry (USD/KWh) by Country 77
Figure Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment Drugs 78
Figure Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis 79
Table Major Buyers of Chemotherapy Induced Peripheral Neuropathy Treatment 80
Figure Setting Pricing Policy 84
Figure Global GDP Growth Rate for 2016 89
Figure Real GDP Growth 2016-2020 annual Average 90
Figure USA GDP 2008-2016 (Billion USD) 91
Figure USA GDP Growth Rate Change 2015-2018 91
Figure EU GDP 2008-2016 (Billion USD) 92
Figure EU GDP Growth Rate Change 2015-2018 92
Figure Germany GDP 2008-2016 (Billion USD) 93
Figure Germany GDP Growth Rate 2015-2018 93
Figure UK GDP 2008-2016 (Billion USD) 93
Figure UK GDP Growth Rate 2015-2018 94
Figure Italy GDP 2008-2016 (Billion USD) 94
Figure Italy GDP Growth Rate 2015-2018 94
Figure France GDP 2008-2016 (Billion USD) 95
Figure France GDP Growth Rate 2015-2018 95
Figure Japan GDP 2008-2016 (Billion USD) 95
Figure Japan GDP Growth Rate 2015-2018 96
Figure China GDP 2008-2016 (Billion USD) 96
Figure China GDP Growth Rate 2015-2018 96
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) and Growth Rate Forecast (2019-2025) 97
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) and Growth Rate Forecast (2019-2025) 98
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) Forecast by Regions (2019-2025) 98
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Regions (2019-2025) 99
Figure North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) and Growth Rate Forecast (2019-2025) 100
Figure North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) and Growth Rate Forecast (2019-2025) 101
Figure Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) and Growth Rate Forecast (2019-2025) 102
Figure Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) and Growth Rate Forecast (2019-2025) 103
Figure Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) and Growth Rate Forecast (2019-2025) 104
Figure Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) and Growth Rate Forecast (2019-2025) 105
Figure South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) and Growth Rate Forecast (2019-2025) 106
Figure South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) and Growth Rate Forecast (2019-2025) 107
Figure Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) and Growth Rate Forecast (2019-2025) 108
Figure Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate Forecast (2019-2025) 109
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) Forecast by Type (2019-2025) 109
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Type (2019-2025) 110
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) Forecast by Type (2019-2025) 110
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share Forecast by Type (2019-2025) 111
Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Unit) Forecast by Application (2019-2025) 111
Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Application (2019-2025) 112
  • Global Veterinarian Supplement Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 24-Jun-2019        Price: US 3480 Onwards        Pages: 121
    Veterinary Calcium Supplements can enhance pet immunity and help pets stay healthy. Veterinary Calcium Supplements include fat supplements, protein supplements, minerals supplements, vitamin supplements, etc. These ingredients are available as chewable tablets or treats, liquids, powders, capsules and in pet food. Scope of the Report: The worldwide market for Veterinarian Supplement is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million......
  • Global Saccharomyces Boulardii Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 24-Jun-2019        Price: US 3480 Onwards        Pages: 115
    Saccharomyces Boulardii is a non-pathogenic probiotic yeast that acts as a temporary flora to protect the gastrointestinal tract and the beneficial organisms of the intestine and has been recognized as antidiarrhoeals, intestinal anti-inflammatory and anti-infective agent. Scope of the Report: The worldwide market for Saccharomyces Boulardii is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019,......
  • Global S-Adenosylmethionine (SAMe) Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 24-Jun-2019        Price: US 3480 Onwards        Pages: 117
    S-Adenosylmethionine (SAMe) is a chemical compound made from methionine, an amino acid also found in protein-rich foods, and adenosine triphosphate (ATP), a nucleic acid and the product of some chemical reactions in body. Now it is a dietary supplement available in the United States. It has also been used as a drug in Europe for the treatment of depression, liver disorders, fibromyalgia, and osteoarthritis. Scope of the Report: The worldwide market for S-Adenosylmethionine ......
  • Global Osteoarthritis Drugs Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 24-Jun-2019        Price: US 3480 Onwards        Pages: 119
    Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by gradual destruction of the articular cartilage, hypertrophy of the bone margins, and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and loss of movement. Medicines for Osteoarthritis Pain are available as pills, syrups, creams or lotions, or they are injected into......
  • Global Hepatic Encephalopathy Drugs Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 24-Jun-2019        Price: US 3480 Onwards        Pages: 116
    Hepatic encephalopathy (HE) is a severe complication of TIPS treatment in patients with cirrhosis and variceal bleeding. Lactulose, is considered the first-line therapeutic agent for treating hepatic encephalopathy. Based on route of administration, Hepatic Encephalopathy Drugs include oral (tablets & solutions) and injections. Scope of the Report: The worldwide market for Hepatic Encephalopathy Drugs is expected to grow at a CAGR of roughly xx% over the next five years, wi......
  • Global Beta-Glucan Nutraceuticals Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 24-Jun-2019        Price: US 3480 Onwards        Pages: 119
    Beta-Glucan comprise a group of ß-D-glucose polysaccharides naturally occurring in the cell walls of cereals, yeast, bacteria, and fungi. It is commonly used for its cholesterol-lowering effects. Scope of the Report: The worldwide market for Beta-Glucan Nutraceuticals is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report fo......
  • Global Cancer Biopharmaceuticals Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    Published: 24-Jun-2019        Price: US 3480 Onwards        Pages: 136
    Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Cancer is a complex invasive genetic disease that causes significant mortality rate worldwide. Cancer drugs are the primary concern in terms of drug development trends. Scope of the Report: The global Cancer Biopharmaceuticals market is valued at xx million USD in 2018 and ......
  • Global Non-oncology Biopharmaceuticals Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    Published: 24-Jun-2019        Price: US 3480 Onwards        Pages: 138
    Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or compl......
  • Global Pain Management Product Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 24-Jun-2019        Price: US 3480 Onwards        Pages: 136
    Pain is complex, so there are many treatment options -- medications, therapies, and mind-body techniques. The classification of pain management drugs includes Opioids and Non-narcotic Analgesics. Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone, hydrocodone, codeine, morphine, and many others. Non-narcotic Analgesics include NSAIDS, anticonvulsants, anti-depressants and o......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs